Melatonin and protection from whole-body irradiation: Survival studies in mice

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 425, Issue 1, 1999, Pages 21-27

  Vijayalaxmi, ^a   Meltz, Martin L ^a   Reiter, Russel J ^b   Herman, Terence S ^a   Kumar K, Sree ^c  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b Armed Forces Radiobiol Res Inst ^*  (United States)

^c ARMED FORCES RADIOBIOLOGY RESEARCH INSTITUTE   (United States)

Author keywords

Gamma radiation; Melatonin; Radioprotection; Survival

Indexed keywords

MELATONIN;

ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; GAMMA IRRADIATION; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIATION PROTECTION; WHOLE BODY RADIATION;

ANIMALS; LETHAL DOSE 50; MALE; MELATONIN; MICE; RADIATION DOSAGE; RADIATION-PROTECTIVE AGENTS; WHOLE-BODY IRRADIATION;

EID: 0033035371     PISSN: 00275107     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0027-5107(98)00246-2     Document Type: Article

References (42)

1. Dale W.M., Gray L.H., Meredith W.J. The inactivation of an enzyme (carboxypeptidase) by X- and α-radiation. Philos. Trans. R. Soc. Lond. A. 242:1949;33-62.
2. Patt H.M., Turee E.B., Straube R.L., Smith D.E. Cysteine protection against X irradiation. Science. 110:1949;213-214.
3. Becq Z.M., Herve A., Lecomte J., Fischer P., Dechamps G., Le Bihan H., Rayet P. Protection contre le rayonnement X par la β-mercaptoethylamine. Arch. Int. Physiol. 59:1951;442-447.
4. E.J. Hall, Radiobiology for the Radiologist, Chap. 11, Radioprotectors, J.B. Lippincott, Philadelphia, 1994, pp. 183-190.
5. Yuhas J.M., Spellman J.M., Culo F. The role of WR-2721 in radiotherapy and/or chemotherapy. Cancer Clin. Trials. 3:1980;211-216.
6. Glover D.J., Riley L., Carmichael K., Spar B., Glick J., Kligerman M.M., Agus Z.S., Slatopolsky E., Attie M., Goldfarb S. Hypocalcemia and inhibition of parathyroid hormone secretion after administration of WR-2721 (a radioprotective and chemoprotective agent). New Engl. J. Med. 309:1983;1137-1141.
7. Kligerman M.M., Glover D.J., Turrisi A.T., Norfleet A.L., Yuhas J.M., Coia L.R., Simone C., Glick J.H., Goodman R.L. Toxicity of WR-2721 administered in single and multiple doses. Int. J. Radiat. Oncol. 10:1984;1773-1776.
8. L.M. Schuchter, J.H. Glick, The current status of WR-2721 (Amifostine): a chemotherapy and radiotherapy protector, in: V.T. DeVita, S. Hellman, S.A. Rosenberg (Eds.), Biologic Therapy of Cancer Updates, Vol. 3, Part 1, J.B. Lippincott, Philadelphia, 1993, pp. 1-10.
9. 2 increases survival in mice following irradiation. Radiat. Res. 109:1987;440-448.
10. Reiter R.J. The pineal gland and its hormones in the control of reproduction in mammals. Endocrine Rev. 1:1980;109-131.
11. Reiter R.J. Pineal melatonin: cell biology of its synthesis and of its physiological interactions. Endocrine Rev. 12:1991;151-180.
12. Reiter R.J. The ageing pineal gland and its physiological consequences. BioEssays. 14:1992;169-175.
13. Reiter R.J., Tang L., Garcia J.J., Munoz-Hoyos A. Pharmacological actions of melatonin in oxygen radical pathophysiology. Life Sci. 60:1997;2255-2271.
14. Pierpoali W.A., Dall'Ara A., Pedrinis E., Regelson W. The pineal control of aging. The effects of melatonin and pineal grafting on the survival of older mice. Ann. N.Y. Acad. Sci. 621:1991;291-313.
15. Tan D.-X., Chen L.D., Poeggeler B., Manchester L.C., Reiter R.J. Melatonin: a potent, endogenous hydroxyl radical scavenger. Endocrine J. 1:1993;57-60.
16. Matuszak Z., Reszka K.J., Chignell C.F. Reaction of melatonin and related indoles with hydroxyl radicals: ESR and spin trapping investigations. Free Radic. Biol. Med. 23:1997;367-372.
17. Stasica P., Ulanski P., Rosiak J.M. Melatonin as a hydroxyl radical scavenger. J. Pineal Res. 25:1998;65-66.
18. Pieri C., Marra M., Moroni F., Recchioni R., Marcheselli F. Melatonin: a peroxyl radical scavenger more effective than vitamin E. Life Sci. 55:1994;271-276.
19. Gilad E., Cuzzocrea S., Zingarelli B., Salzman A.L., Szaba C. Melatonin is a scavenger of peroxynitrite. Life Sci. 60:1997;169-174.
20. Reiter R.J. Antioxidant actions of melatonin. Adv. Pharmacol. 38:1997;103-117.
21. Vijayalaxmi, Reiter R.J., Meltz M.L. Melatonin protects human blood lymphocytes from radiation-induced chromosome damage. Mutat. Res. 346:1995;23-31.
22. Vijayalaxmi, Reiter R.J., Sewerynek E., Poeggeler B., Leal B.Z., Meltz M.L. Marked reduction of radiation-induced micronuclei in human blood lymphocytes pretreated with melatonin. Radiat. Res. 143:1995;102-106.
23. Vijayalaxmi, Reiter R.J., Herman T.S., Meltz M.L. Melatonin and radioprotection from genetic damage: in vivo/in vitro studies with cells from human volunteers. Mutat. Res. 371:1996;221-228.
24. Vijayalaxmi, Reiter R.J., Herman T.S., Meltz M.L. Melatonin reduces gamma radiation-induced primary DNA damage in human blood lymphocytes. Mutat. Res. 397:1998;203-208.
25. K.S. Kumar, Y.N. Vaishnav, C. Smith, E.P. Clark, Radiation injury and antioxidant mechanisms of protection, in: S. Nigam, K.V. Honn, L.J. Marnett, T.L. Walden (Eds.), Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation, and Radiation Injury, Kluwer Academic, Norwell, 1993, pp. 333-339.
26. Weiss J.F., Kumar K.S., Walden T.L., Neta R., Landauer M.R., Clark E.P. Advances in radioprotection through the use of combined agent regimens. Int. J. Radiat. Biol. 57:1990;709-722.
27. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J. Amer. Stat. Assoc. 53:1958;457-481.
28. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemo. Rep. 50:1966;163-170.
29. Breslow N. A generalized Kruskal-Wallis test for comparing k samples subject to unequal patterns of censorship. Biometrika. 57:1970;579-594.
30. Tarone R.E., Ware J. On distribution-free tests for equality of survival distributions. Biometrika. 64(1):1977;156-160.
31. J.J. Broerse, T.J. MacVittie, Response of Different Species to Total-Body Irradiation, Martin Nijhoff, Boston, 1984, pp. 229-232.
32. Anderson R.E., Warner N.L. Ionizing radiation and the immune response. Adv. Immunol. 24:1976;215-335.
33. M.L. Patchen, Immunomodulators and cytokines: their use in the mitigation of radiation-induced hemopoietic injury, in: E.A. Bump, K. Malaker (Eds.), Radioprotectors: Chemical, Biological, and Clinical Perspectives, CRC Press, New York, 1997, pp. 213-236.
34. Caroleo M.C., Frasca D., Nistico G., Doria G. Melatonin as immunomodulator in immunodeficient mice. Immunopharmacology. 23:1992;81-89.
35. G. Maestroni, A. Conti, Melatonin in relation to the immune system, in: H.S. Yu, R.J. Reiter (Eds.), Melatonin Biosynthesis, Physiological Effects and Clinical Applications, CRC Press, New York, 1993, pp. 289-309.
36. Lissoni P., Pittalis G., Brivio F., Barni S., Tancini G., Giudici G., Biondi A., Conti A., Maestroni G. In vitro modulatory effects of interleukin-3 on macrophage activation induced by interleukin-2. Cancer. 71:1993;2076-2081.
37. Anwar M.M., Mahfouz H.A., Sayed A.S. Potential protective effects of melatonin on bone marrow of rats exposed to cytotoxic drugs. Comp. Biochem. Physiol. A. 119:1998;493-501.
38. Vijayalaxmi, Reiter R.J., Herman T.S., Meltz M.L. Melatonin: possible mechanisms involved in its 'radioprotective' effect. Mutat. Res. 404:1998;187-189.
39. Blickenstaff R.T., Brandstadter S.M., Reddy S., Witt R. Potential radioprotective agents: 1. Homologs of melatonin. J. Pharm. Sci. 83:1994;216-218.
40. Barchas J., DaCosta F., Spector S. Acute pharmacology of melatonin. Nature (London). 214:1967;919-920.
41. Vijayalaxmi, Reiter R.J., Leal B.Z., Meltz M.L. Effect of melatonin on mitotic and proliferation indices, and sister chromatid exchange in human blood lymphocytes. Mutat. Res. 351:1996;187-192.
42. Roberts L. Radiation accident grips Goiania. Science. 238:1987;1028-1031.